Novo's New US Chief on Lilly's Rival Weight-Loss Pill

Bloomberg
Loading video player...
Novo's New US Chief on Lilly's Rival Weight-Loss Pill
Bloomberg
Written by Bloomberg
Share

Novo Nordisk Executive Vice President for US Operations Jamey Millar discusses the US approval of competitor Eli Lilly's obesity pill, the expansion of the GLP-1 category, and the rollout of a new subscription model. He talks with Katie Greifeld for "The Close."

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.